These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 10232336)

  • 1. Preventing HIV-1: lessons from Mwanza and Rakai.
    Nicoll A; Johnson AM; Adler MW; Laga M
    Lancet; 1999 May; 353(9163):1522; author reply 1523-4. PubMed ID: 10232336
    [No Abstract]   [Full Text] [Related]  

  • 2. Preventing HIV-1: lessons from Mwanza and Rakai.
    Kvåle G
    Lancet; 1999 May; 353(9163):1522-3; author reply 1523-4. PubMed ID: 10232337
    [No Abstract]   [Full Text] [Related]  

  • 3. Control of sexually transmitted diseases for HIV-1 prevention: understanding the implications of the Mwanza and Rakai trials.
    Grosskurth H; Gray R; Hayes R; Mabey D; Wawer M
    Lancet; 2000 Jun; 355(9219):1981-7. PubMed ID: 10859054
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interpretation of the Mwanza and Rakai STI trials.
    O'Farrell N
    Bull World Health Organ; 2001; 79(5):482. PubMed ID: 11417045
    [No Abstract]   [Full Text] [Related]  

  • 5. Rakai trial showers sparks over STD-HIV link.
    AIDS Alert; 1998 Oct; 13(10):suppl 1-2. PubMed ID: 11365873
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Determinants of the impact of sexually transmitted infection treatment on prevention of HIV infection: a synthesis of evidence from the Mwanza, Rakai, and Masaka intervention trials.
    Korenromp EL; White RG; Orroth KK; Bakker R; Kamali A; Serwadda D; Gray RH; Grosskurth H; Habbema JD; Hayes RJ
    J Infect Dis; 2005 Feb; 191 Suppl 1():S168-78. PubMed ID: 15627227
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preventing HIV infection: lessons from Mwanza and Rakai.
    Hitchcock P; Fransen L
    Lancet; 1999 Feb; 353(9152):513-5. PubMed ID: 10028974
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interpretation of the Mwanza and Rakai STD trials.
    Hayes R; Grosskurth H; Mabey D
    Bull World Health Organ; 2001; 79(5):482-3. PubMed ID: 11417046
    [No Abstract]   [Full Text] [Related]  

  • 9. Community-based trials of sexually transmitted disease treatment: repercussions for epidemiology and HIV prevention.
    Hudson CP
    Bull World Health Organ; 2001; 79(1):48-58. PubMed ID: 11217667
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preventing HIV-1: lessons from Mwanza and Rakai.
    Matthys F; Boelaert M
    Lancet; 1999 May; 353(9163):1523-4. PubMed ID: 10232338
    [No Abstract]   [Full Text] [Related]  

  • 11. Empirical observations underestimate the proportion of human immunodeficiency virus infections attributable to sexually transmitted diseases in the Mwanza and Rakai sexually transmitted disease treatment trials: Simulation results.
    Orroth KK; White RG; Korenromp EL; Bakker R; Changalucha J; Habbema JD; Hayes RJ
    Sex Transm Dis; 2006 Sep; 33(9):536-44. PubMed ID: 16778738
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Mwanza trial: Dr. Hudson replies.
    Hudson CP
    Bull World Health Organ; 2001; 79(8):793-4. PubMed ID: 11545339
    [No Abstract]   [Full Text] [Related]  

  • 13. Mass treatment for STDs has mixed results: some STD rates fall, but HIV incidence remains unchanged.
    Bowersox J
    NIAID AIDS Agenda; 1998 Aug; ():10-1. PubMed ID: 11365726
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Complementary hypothesis concerning the community sexually transmitted disease mass treatment puzzle in Rakai, Uganda.
    Boily MC; Lowndes CM; Alary M
    AIDS; 2000 Nov; 14(16):2583-92. PubMed ID: 11101071
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Can population differences explain the contrasting results of the Mwanza, Rakai, and Masaka HIV/sexually transmitted disease intervention trials?: A modeling study.
    White RG; Orroth KK; Korenromp EL; Bakker R; Wambura M; Sewankambo NK; Gray RH; Kamali A; Whitworth JA; Grosskurth H; Habbema JD; Hayes RJ
    J Acquir Immune Defic Syndr; 2004 Dec; 37(4):1500-13. PubMed ID: 15602129
    [TBL] [Abstract][Full Text] [Related]  

  • 16. More community-based trials of STD control or more appropriate interventions: which is the priority for preventing HIV-1 infection in developing countries?
    Alary M
    Bull World Health Organ; 2001; 79(1):59-60. PubMed ID: 11217669
    [No Abstract]   [Full Text] [Related]  

  • 17. Cost-effectiveness of improved treatment services for sexually transmitted diseases in preventing HIV-1 infection in Mwanza Region, Tanzania.
    Gilson L; Mkanje R; Grosskurth H; Mosha F; Picard J; Gavyole A; Todd J; Mayaud P; Swai R; Fransen L; Mabey D; Mills A; Hayes R
    Lancet; 1997 Dec 20-27; 350(9094):1805-9. PubMed ID: 9428251
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Riddle of the Sphinx revisited: the role of STDs in HIV prevention.
    Barnabas RV; Wasserheit JN
    Sex Transm Dis; 2009 Jun; 36(6):365-7. PubMed ID: 19434009
    [No Abstract]   [Full Text] [Related]  

  • 19. Empirical observations underestimate the proportion of HIV infections attributable to sexually transmitted diseases in Mwanza and Rakai STD treatment trials: simulation results.
    Gray RH; Serwadda D; Wawer MJ
    Sex Transm Dis; 2007 Jan; 34(1):61; author reply 62. PubMed ID: 17195759
    [No Abstract]   [Full Text] [Related]  

  • 20. Comparison of STD prevalences in the Mwanza, Rakai, and Masaka trial populations: the role of selection bias and diagnostic errors.
    Orroth KK; Korenromp EL; White RG; Changalucha J; de Vlas SJ; Gray RH; Hughes P; Kamali A; Ojwiya A; Serwadda D; Wawer MJ; Hayes RJ; Grosskurth H
    Sex Transm Infect; 2003 Apr; 79(2):98-105. PubMed ID: 12690128
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.